Informationen på denna sida är avsedd för journalister, press och media. Klicka ja för att komma till nyhetsrummet. Klickar du nej kommer du tillbaka till mynewsdesk.com.
On 18 November 2014, AstraZeneca will provide an update for institutional investors and financial analysts on the progress against the company’s strategic priorities of achieving scientific leadership and returning to growth.
You are invited to join a short media teleconference at 10:00 CET (09:00 GMT) when Pascal Soriot, CEO, will provide some highlights from the Investor Day update, which will follow later in the afternoon. The media call will include time for a question and answer session, during which Pascal will be joined by members of the AstraZeneca senior executive team.
The conference call ID is # 21108647 and dial-in numbers are as follows:
Please dial-in 10 minutes before the call is due to start.
UK Free phone: 0800 6942370, Local rate: 01452 557749
US Free phone: 1 866 9777645, Local rate: 1 631 5142520
Sweden Free phone: 0200 883079, Local rate: 0850 619578
If you intend to participate in the media call please let Melissa Gardiner know by emailing melissa.gardiner@astrazeneca.com or calling +44 (0) 20 7604 8465.
------------------------------------------------------------------------------------------------------
The Investor Day presentations for institutional investors and financial analysts will follow at 12:30 GMT, finishing at approximately 18:15 GMT. Media may join the call/webcast in ‘listen-only’ mode.
Conference call
As the call is lengthy, please pre-register before the start of the meeting using the link below:
https://emea.directeventreg.com/der/validateConferenceId.action
Upon registering, you will be provided with the call details and a Registrant ID.
Slides will be available to download on the AstraZeneca Investor Relations website 15 minutes prior to the start of the presentations at: www.astrazeneca.com/Investors
Webcast
You can also join a live video webcast of the presentations from the AstraZeneca Investor Relations website, as above. Please pre-register for the webcast from Monday 17 November.
AstraZeneca (LSE/STO/Nasdaq: AZN) är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel för sjukdomar inom terapiområdena Onkologi, Sällsynta sjukdomar och Bioläkemedel, inklusive kardiovaskulära sjukdomar, njursjukdomar och metabola sjukdomar (CVRM) samt Andningsvägar och Immunologi. AstraZeneca är baserat i Cambridge i Storbritannien och bedriver verksamhet i över 100 länder. Dess innovativa läkemedel används av miljontals patienter över hela världen.